Advanced Multidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases

What this Trial Is About

Researchers are studying interstitial lung diseases (ILDs), a group of chronic conditions that cause serious lung and heart problems, including early heart complications that often go unnoticed. These heart issues can include ischemic heart disease, worsening of artery health, and right heart dysfunction due to high lung blood pressure. Early detection and accurate assessment of both lung and heart damage are important to prevent disease worsening and improve patient outcomes. The study is observational and uses advanced multidimensional and ultra-high resolution computed tomography (CT) scans to non-invasively evaluate and measure lung and heart damage in patients with progressive fibrosing ILDs. The goal is to develop a low-dose CT imaging protocol that can characterize lung tissue changes and discover new imaging biomarkers of lung disease severity. Additionally, researchers aim to study the prevalence and types of heart disease in ILD patients and create a CT-based risk assessment tool. Participants will undergo CT scans over a period of months to measure lung and heart conditions using these new imaging methods. The main focus is to assess lung tissue damage between months 2 and 12, then evaluate heart disease features and their link to lung severity between months 3 and 16. Later, a multiparametric CT algorithm for risk stratification will be developed from months 19 to 24. Throughout the study, data collection will be done with informed consent, and participants will be monitored for safety and disease progression.

Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases